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Abstract: The nasopharynx is the ecological niche where evolution towards resistance occurs 
in respiratory tract isolates. Dynamics of different bacterial populations in   antibiotic-free 
  multibacterial niches are the baseline that antibiotic treatments can alter by shifting the 
  competitive balance in favor of resistant populations. For this reason, antibiotic resistance is 
increasingly being considered to be an ecological problem. Traditionally, resistance has implied 
the need for development of new antibiotics for which basic efficacy and safety data are required 
prior to licensing. Antibiotic development is mainly focused on demonstrating   clinical efficacy 
and setting susceptibility breakpoints for efficacy prediction. However, additional informa-
tion on pharmacodynamic data predicting absence of selection of resistance and of resistant 
subpopulations, and specific surveillance on resistance to core antibiotics (to detect emerging 
resistances and its link with antibiotic consumption in the community) are valuable data in 
defining the role of a new antibiotic, not only from the perspective of its therapeutic potential but 
also from the ecologic perspective (countering resistances to core antibiotics in the community). 
The documented information on cefditoren gleaned from published studies in recent years is 
an example of the role for an emerging oral antibacterial facing current antibiotic resistance in 
community-acquired respiratory tract infections.
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Nasopharyngeal colonization  
and prevalent isolates
Mucosal surfaces are simultaneously colonized by multiple species, with an   intricate 
balance in the nasopharynx between Streptococcus pneumoniae, Streptococcus 
pyogenes, Haemophilus influenzae, and other nasopharyngeal flora. These bacterial 
species share three characteristics, ie, they colonize the nasopharynx of humans as 
their exclusive host, are exogenously transmitted to colonize the nasopharynx of 
new hosts, and are common etiological agents (most prevalent isolates) of bacterial 
community-acquired respiratory tract infections when they endogenously migrate to 
different ecosystems or when changes within their natural ecosystem occur. Thus the 
upper respiratory tract, with its commensal flora, acts both as a colonization defense 
mechanism and as a primary bacterial source for respiratory tract infections, S. pyogenes 
being the etiologic agent of tonsillitis, and S. pneumoniae and H. influenzae being the 
causative agents of otitis media, sinusitis, and lower respiratory tract infections, ie, 
acute exacerbation of chronic bronchitis (AECB) and pneumonia.
Carriage of these common respiratory isolates depends on multiple factors, such as 
active or passive smoking, crowding, age, bacterial fitness, specific   vaccination, and Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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  bacterial interference in antibiotic-free niches.1–3   Approximately 
80% of healthy individuals carry H. influenzae,4 with mul-
tiple strains in 50% positive samples and a high turnover of 
strains.2,5 In the case of S. pneumoniae, carriage ranges from 
10% to 40% in an age-dependent manner,6 with lower percent-
ages of multiple strains in the same sample7 and a duration 
of   nasopharyngeal carriage depending on age, seasonality, 
  resistance to   penicillin, serotype, and simultaneous carriage by 
other family members.8,9 S. pyogenes frequently colonizes the 
nasopharynx of asymptomatic persons, with carriage rates of 
15%–20% in school children (crowding favors interpersonal 
spread), but this is considerably lower in adults.10
Bacterial evolution towards 
resistance in respiratory tract 
isolates
The nasopharynx is the ecological niche where evolution 
towards resistance occurs in respiratory tract isolates. 
The evolution of antibiotic resistance involves two pro-
cesses, ie, emergence and spread.11,12 Resistance to β-lactams 
and macrolides is mostly due to acquisition of exogenous 
resistance genes, and has been described in S. pneumo-
niae and H. influenzae (in both cases, resistance to both 
β-lactams and to macrolides) and in S. pyogenes (resistance 
to macrolides),13–16 with de novo resistance occurring rarely 
within a given host in a susceptible bacterial population.13 
In contrast, resistance to fluoroquinolones in S. pneumoniae 
arises within a given host due to point mutations.13
Evolution is based on production of variation, management 
of variation, and natural selection of variants.17 Dynamics of 
different bacterial populations in antibiotic-free niches are the 
baseline that antibiotic treatments can alter18,19 by shifting the 
competitive balance in favor of resistant populations. For this 
reason, antibiotic resistance is increasingly regarded as an eco-
logic problem. Once resistance has emerged, physiologic con-
centrations of different antibiotics may select resistant strains 
by eradicating the susceptible ones (thus unmasking resistant 
populations),19 or by selecting intrastrain-resistant subpopula-
tions.20 Because multiple individuals harbor multiple bacterial 
populations exhibiting different degrees of antibiotic resistance 
at the community level, the prevalence of resistance is directly 
related to antibiotic consumption in the community.21
Antibiotic consumption as the 
driver of resistance: a global 
problem
Infection, mainly of the respiratory tract,22,23 is the most   frequent 
reason for seeking medical attendance in the   community. 
Around 85%–90% of antibiotic consumption occurs in the 
community, and 80% of this consumption is for the treatment 
of respiratory tract infections.24 Antibiotic consumption has 
been associated with resistance selection.21 Consumption of 
β-lactams and macrolides has been associated with penicillin/
erythromycin resistance in S. pneumoniae, both temporally25 
and geographically,26 with high correlations between penicil-
lin/erythromycin resistance and consumption of long half-life 
macrolides and second-generation oral cephalosporins.25,26 
Associations between ampicillin/amoxicillin resistance in 
H. influenzae and Moraxella catarrhalis and consumption 
of aminopenicillins (with or without clavulanic acid),27,28 as 
well as the association between erythromycin resistance in S. 
pyogenes and consumption of long half-life macrolides, have 
also been described.29,30
Because antibiotic consumption in the community has 
been associated with resistance prevalence, in geographic 
locations with high antibiotic consumption, eg, Spain, 
  associations between the resistance rates found in   different 
bacterial species of respiratory tract isolates could be 
expected. In Spain, penicillin resistance in S. pneumoniae has 
been significantly associated with erythromycin resistance 
(due to the coresistance selection phenomenon),31,32 and with 
ampicillin resistance in H. influenzae (due to the phenomenon 
of coselection of resistance). In addition, geographically, 
erythromycin resistance in S. pyogenes was significantly 
related to penicillin and/or erythromycin resistance in 
S. pneumoniae and to ampicillin resistance in H. influenzae.13 
Considering these associations, in Spain, as in other coun-
tries, resistance should be considered as a global problem 
with regard to respiratory isolates in the community.
Current resistances in respiratory 
isolates in the community
Streptococcus pneumoniae
Penicillin/erythromycin nonsusceptibility in S. pneumoniae 
is mainly clustered in a reduced number of serotypes. In 
invasive isolates, the increase in the prevalence of antibiotic 
nonsusceptibility and of certain serotypes that occurred in the 
1980s and 1990s related to antibiotic consumption reversed 
in the 2000s when the seven-valent conjugate pneumococcal 
vaccine (PCV7) (including serotypes most associated with 
penicillin/erythromycin nonsusceptibility) was introduced 
for childhood immunization.33,34 The introduction of PCV7 
produced not only a dramatic reduction in the incidence of 
invasive pneumococcal disease, but also a marked decrease in 
PCV7 serotypes which consequently affected penicillin and 
erythromycin nonsusceptibility in invasive isolates.34,35Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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With respect to noninvasive isolates in Spain, surveillance 
including high number of isolates has shown that nonsuscep-
tibility to penicillin was 45%–50% from 1998 to 2002, with 
full oral penicillin resistance rates of approximately 20%.31,36 
Amoxicillin nonsusceptibility remained around 10% in 
this period but, among full penicillin-resistant isolates, this 
rate increased to around 40%.31,36 These penicillin-resistant 
isolates exhibited nearly 100% resistance to oral second-
generation cephalosporins, eg, cefaclor or cefuroxime, and 
55% resistance to macrolides.31 In a worldwide surveillance 
(1999–2004) of isolates from community-acquired infections 
in patients $65 years (including a high number of noninva-
sive isolates), penicillin nonsusceptibility was approximately 
22% in Eastern Europe and North America, and up to about 
60% in Far East.37
The emergence of amoxicillin resistance within pre-existing 
penicillin-resistant clones has also been related to macrolide 
and ciprofloxacin resistance,31,36,38 with reports of spread of 
troublesome clones with MIC values of amoxicillin higher than 
those of penicillin,39 mainly the four Spanish multiresistant ones 
(Spain23F-1, Spain6B-2, Spain9V-3, and Spain14-5).
Erythromycin resistance in pneumococci has remained 
relatively stable in Spain, with rates of around 35% between 
1996 and 2002 in surveillances including high numbers of 
noninvasive isolates.31,36,40 The main resistant phenotype is 
MLSB (approximately 90%), with M-efflux representing 
approximately 10%,31 thus erythromycin resistance also 
implies clarithromycin and azithromycin resistance. Similar 
resistance rates are found in the US (30.0%–35.3%), with 
an increase in highly resistant strains in recent years, and a 
decrease in M-efflux-mediated resistant strains.41
In the same surveillance, ciprofloxacin resistance 
(MIC $ 4 µg/mL) was around 5%–7%,31,37 but .85% of these 
isolates were susceptible to levofloxacin and   moxifloxacin. 
From these data it is deduced that rates of nonsusceptibility to 
respiratory fluoroquinolones (levofloxacin and moxifloxacin) 
are not .1%.36 Worldwide, a 2.2% nonsusceptibility rate has 
been reported for levofloxacin.37
Multiple resistance, defined as full resistance to two or 
more of the six classes of antibacterials represented by peni-
cillin, erythromycin, cefuroxime, tetracyclines, trimethoprim-
sulfamethoxazole, and levofloxacin, has been reported in 
S. pneumoniae, with rates as high as 19.1% in North America, 
27.7% in Western Europe, and 80.4% in the Far East.37
Streptococcus pyogenes
S. pyogenes is highly susceptible to all β-lactams.   Prevalence 
of resistance to erythromycin was 37% in 2001–2002 
in Spain,31 with the M-efflux phenotype being the most 
prevalent (86%), and with 14% of strains from the MLSB 
phenotype showing constitutive resistance.31 Since both 
mechanisms imply resistance to 14- and 15-membered 
macrolides, erythromycin resistance implies resistance to 
azithromycin and clarithromycin.42
In the last few years, S. pyogenes isolates showing low-
level resistance to fluoroquinolones have been reported,43–45 
with infrequent high-level resistance to date. However, due 
to the high prevalence of isolates harboring parC mutation, 
in the near future the frequency of high-level resistance 
may increase because only one new mutation in gyrA is 
required.46 In Spain, there has been a marked increase in the 
number of isolates with low-level resistance, and isolates 
showing high-level resistance have also been detected.47
Haemophilus influenzae
The basic problem of resistance in this species is defined by 
ampicillin as the resistance marker. According to   successive 
surveillance studies carried out from 1996 to 2002, 
  approximately 25% of H. influenzae isolates are resistant 
to ampicillin in Spain.31,48,49 Up to 80% of these ampicillin-
resistant isolates produce β-lactamases (TEM-1, TEM-2, and 
with lower frequency ROB-1) that are inhibited by clavulanic 
acid. The remaining 20% ampicillin-resistant isolates (5% of 
all H. influenzae isolates in Spain) are resistant to ampicillin 
due to mutations in the ftsI gene that cause alterations in the 
amino acid sequences of penicillin-binding protein 3 (PBP3).50 
This resistance genotype defines BLNAR (β-lactamase nega-
tive ampicillin-resistant) strains and since alterations in PBP3 
preclude the adequate binding of ampicillin and amoxicillin, 
BLNAR strains are also resistant to amoxicillin–clavulanic 
acid, ampicillin–sulbactam, cefaclor, and cefuroxime.51
Both mechanisms of resistance, ie, β-lactamase 
  production and mutations in the ftsI gene, are present in 
BLPACR (β-lactamase positive amoxicillin–clavulanic acid 
resistant) strains. Among Spanish isolates, according to data 
from different studies, there is an increasing prevalence of 
BLNAR (from 10% in 1997–1998 to approximately 30% in 
2004–2005) and to a lesser extent BLPACR phenotypes,52,53 
in relation to β-lactam consumption over time, mainly 
  amoxicillin with or without clavulanic acid.53
Efficacy prediction for commonly 
used antibiotics
While “microbiologic breakpoints” detect wild-type 
bacterial populations that do not harbor any acquired 
or selected resistance to the antibacterial examined, Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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  “pharmacokinetic/pharmacodynamic (PK/PD) breakpoints” 
have been associated with microbial killing as an endpoint 
to predict bacterial eradication and clinical outcome.54–56 
By relating pharmacokinetic variables and susceptibility 
data (ie, antibiotic drug exposure relative to in vitro MIC), 
PK/PD breakpoints indicate the highest MIC value that pro-
duces the adequate value for the relevant PK/PD parameter. 
In the case of S. pneumoniae and H. influenzae, and β-lactams 
or macrolides, the time (expressed as the percentage of the 
dosing interval) that antibiotic concentrations exceed the 
value of MIC (T . MIC) is the parameter predicting efficacy, 
with a cutoff value of 40%, but in the case of fluoroquinolo-
nes, the parameter is the relationship between the area under 
the serum concentration-time curve (AUC) and the MIC 
(AUC/MIC), with a cutoff value of 30.
In a multicenter surveillance study in Spain, similar sus-
ceptibility rates were found for S. pneumoniae by applying 
the breakpoints defined by the Clinical Laboratory Standards 
Institute (CLSI) and PK/PD breakpoints for amoxicillin 
(approximately 92%), cefuroxime–axetil (about 67%), eryth-
romycin and azithromycin (about 64%), but not for cefaclor 
(61.7% versus 40.5%).31
For H. influenzae, the use of CLSI or PK/PD breakpoints 
does not influence susceptibility rates of ciprofloxacin 
(100%), ampicillin (about 75%) or amoxicillin–clavulanic 
acid (about 97%), but changes the rates of susceptibility 
to cefuroxime–axetil (from 100% to 72.8%) and cefaclor 
(from 82.1% to 1.4%), with lower rates when applying 
PK/PD breakpoints.31 In the case of macrolides, differences 
are clearly evident, with reductions in susceptibility rates to 
clarithromycin and azithromycin from 72% 100%, respec-
tively, by applying CLSI breakpoints, to 2.2% and 1.2%, 
respectively, by applying PK/PD breakpoints.31
Management strategies 
to overcome resistance
Under circumstances of a global problem of resistance among 
prevalent isolates in community respiratory pathogens, there 
is a need for strategies countering resistance, ie, selection 
of coresistance within the same species and coselection of 
resistances between species. One possible strategy is based 
on increasing oral doses for the treatment of respiratory tract 
infections in the community that, although not adequate for 
macrolides (high-level resistance), has been used in the case 
of amoxicillin–clavulanic acid, with the development of new 
formulations adequate to minimize amoxicillin resistance 
in S. pneumoniae, but inadequate to counter BLNAR and 
BLPACR diffusion among H. influenzae. Another   possible 
strategy is the development of new antibiotics with adequate 
pharmacokinetics and high in vitro activity against commu-
nity prevalent isolates, achieving values of pharmacodynamic 
parameters predicting bacterial eradication. The need for new 
antibiotics in the community is mainly defined by antimicro-
bial activity against the prevalent resistance phenotypes rather 
than the activity against phenotypes susceptible to antibiotics 
previously used in the community. For this reason new anti-
biotics for the treatment of respiratory tract infections should 
demonstrate in vitro activity against S. pneumoniae not sus-
ceptible to previous antibiotics (with specific phenotypes of 
resistance and clones) and H. influenzae nonsusceptible to 
ampicillin (BLNAR, BLPACR).
Cefditoren for community-acquired 
respiratory tract infections
In vitro activity
Cefditoren is an oral, third-generation aminothiazolyl 
cephalosporin with structural components similar to those 
of first- and third-generation cephalosporins.57 In general, 
cephalosporins differ from one another mainly in the 
two side chain components attached to the cephem scaffold. 
In cefditoren, the group attached at the C-7 position affords 
activity against Gram-negative microorganisms, whereas 
the one attached at the C-3 position affords activity against 
Gram-positive bacteria (not seen in other non-first-generation 
cephalosporins).
In vitro studies carried out to explore the activity of 
  cefditoren included not only a high number of strains iso-
lated in the community but also a significant number of 
strains with troublesome resistance phenotypes/genotypes. 
Cefditoren exhibited potent intrinsic activity, inhibiting all 
penicillin-susceptible S. pneumoniae at concentrations of 
0.12 µg/mL (MIC90 of #0.03 µg/mL).58 At concentrations 
of 0.5 µg/mL, cefditoren inhibited 92.6% of cefotaxime 
nonsusceptible pneumococci and .97% of strains nonsus-
ceptible to the other antibiotics (penicillins, cephalosporins, 
macrolides, ketolides, and quinolones).59 With respect to 
Spanish multiresistant clones, cefditoren exhibited an MIC90 
of #0.5 µg/mL against strains belonging to Spain23F-1 (with 
susceptibility rates to amoxicillin–clavulanic acid of 4.2%, to 
macrolides of 66.7%, and to cefotaxime of 95.8%), Spain9V-3 
(with susceptibility rates to amoxicillin–clavulanic acid of 
30%, to macrolides of 81.7%, and to cefotaxime of 85%), and 
Spain6B-2 (with susceptibility rates to amoxicillin–clavulanic 
acid of 6.8%, to macrolides of 4.5%, and to cefotaxime 
of 81.8%).60 Against the most troublesome strains of the 
clone Spain14-5 (that exhibited susceptibility rates of 7.3% Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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to amoxicillin, 4.9% to macrolides, 57.3% to cefotaxime, 
and only 65.9% to   levofloxacin), cefditoren MIC50/MIC90 
values were 0.5/1 µg/mL, one dilution lower than values for 
cefotaxime.60
Against H. influenzae, while amoxicillin–clavulanic 
acid and cefuroxime MIC50/MIC90 values increased from 
0.5/1 µg/mL for ampicillin-susceptible strains to 2/4 and 
1/4 µg/mL, respectively, for BLNAR strains, and up to 4/8 
and 4/16 µg/mL, respectively, for BLPACR strains, cefdito-
ren exhibited similar intrinsic activity to that of cefotaxime 
against ampicillin-susceptible, BLNAR and BLPACR strains 
with MIC50/MIC90 values of 0.03/0.06 µg/mL.61,62 The excel-
lent intrinsic activity of cefditoren against H. influenzae has 
recently been confirmed in a multicenter European study 
testing 665 clinical isolates, with MIC50/MIC90 for cefditoren 
of #0.06/#0.06 µg/mL.63
Pharmacokinetics and 
pharmacodynamics
In a Phase I study administering a single dose of 400 mg 
cefditoren–pivoxil with food to 10 healthy Caucasian male 
volunteers, Cmax was 3.7 ± 0.7 µg/mL, Tmax was 2 hours, 
AUC0–α was 12.5 ± 1.6 µg × hour/mL, and the elimination 
half-life was 1.54 ± 0.20 hours.64 In the theoretical pharmaco-
dynamic assessment performed with these data, considering 
T . MIC as the relevant PK/PD parameter, the 400 mg bid 
regimen of cefditoren–pivoxil obtained a value of T . MIC 
for total drug of approximately 55% for MIC 0.5 µg/mL, 
68% for MIC 0.25 µg/mL, 81% for MIC 0.12 µg/mL and 
94% for MIC 0.06 µg/mL.64
This pharmacodynamic analysis was performed consider-
ing the total drug. Cefditoren is a highly protein-bound anti-
microbial with 88% protein binding.57 It has been suggested 
that only the unbound fraction of an antimicrobial is active 
in vitro, but the reversibility of protein binding implies that 
limitation of activity may be far from absolute, even in highly 
protein-bound agents.65 To explore the activity of cefditoren 
in the presence of human albumin, a one-compartmental in 
vitro dynamic model simulating the cefditoren 400 mg bid 
serum profile over 24 hours, using media consisting of 75% 
human serum and 25% broth with albumin at physiologic 
concentration (4.9 g/dL), was used.66 Antibacterial activity 
was determined over time against S. pneumoniae exhibiting 
MICs of 0.25 and 0.5 µg/mL.66 The cefditoren protein bind-
ing in the system was 87.1%, thus potentially interfering 
with cefditoren activity as in in vivo situations. Under these 
circumstances, at 24 hours, initial inoculum reductions for 
strains with MIC of 0.25 µg/mL was .99.9% (bactericidal 
activity), and ranged from 53% to 97% (an effect higher than 
simply bacteriostatic) for strains with MIC 0.5 µg/mL.66
For extrapolation to humans, a Monte Carlo simulation, 
ie, the method for determining the probability to achieve a 
specific value of a PK/PD index in the general population, was 
performed using cefditoren data from a Phase I study,64 and 
considering both total and free (calculated using the rate of 
protein binding) concentrations of cefditoren.67   Considering 
the target attainment of T . MIC $ 40% (as predictive 
of efficacy),68,69 cefditoren covered (.90%   probability to 
achieve this value of T . MIC) strains with MIC values of 
#0.5 µg/mL (total drug), and #0.12 µg/mL (free drug). 
When the bacteriostatic target attainment (33% T . MIC)70 
was considered, based on definitions of “susceptibility” 
by the FDA71 and CLSI51 as “pathogen likely inhibition by 
blood concentrations”, cefditoren had a .90% probability 
to achieve this bacteriostatic endpoint for MICs #0.5 µg/mL 
and #0.25 µg/mL for total and free drug, respectively.67
Cefditoren breakpoints
Experimental data (in vitro susceptibility and PK/PD 
  experimental data) and Monte Carlo extrapolations are 
  valuable data for assessing potential breakpoints for 
  cefditoren. Different values have been proposed or defined 
for cefditoren. While breakpoint values proposed by the FDA 
are #0.12 µg/mL for susceptibility and $0.5 µg/mL for 
resistance, some authors have suggested cefditoren suscep-
tibility breakpoint values of #0.5 µg/mL or #1 µg/mL,72–74 
  considering cefditoren MIC90 values lower than the   breakpoint 
values for parenteral third-generation   cephalosporins and 
the pharmacokinetics of cefditoren. Although nowadays 
there are no established breakpoints defined by the CLSI 
or the   European Committee on Antimicrobial   Susceptibility 
  Testing,   experimental and Monte Carlo results are in accor-
dance with the susceptibility breakpoint approved by the 
Spanish Agency during the registration procedure in Europe 
(susceptibility #0.5 µg/mL).75 With this breakpoint value, 
100% isolates of H. influenzae and S. pyogenes and 94% of 
S. pneumoniae are covered in Spain.76
Clinical data on cefditoren 
in community-acquired 
respiratory tract infections
Upper respiratory tract infections
Data from all six clinical trials carried out during the 
clinical development of cefditoren in upper respiratory 
tract   infections were combined in a pooled analysis.77 With Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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respect to pharyngotonsillitis, no significant differences in 
clinical response were found between cefditoren and peni-
cillin V, with success rates ranging from 89.4% to 95.3% 
when pooling data from the three comparative multicenter 
studies (two previously published)78,79 already performed.77 
Eradication of S. pyogenes was higher with cefditoren at 
the end of therapy (90.4% versus 82.7%; P = 0.002) and 
at the end of follow-up (84.7% versus 76.7%; P = 0.008), 
although statistical significance (set at P , 0.001) was not 
reached.77
Similarly, in acute sinusitis, no differences in clinical 
response were found between cefditoren and comparators 
(cefuroxime or amoxicillin-clavulanic acid) both at the end 
of therapy (80.2% versus 84.8%) and at the end of follow-up 
(71.2% versus 77.4%) pooling data from the three studies 
(one previously published)80 performed during the clinical 
development of cefditoren.77
Lower respiratory tract infections
Seven studies were carried out in the clinical development of 
cefditoren for the treatment of lower respiratory tract infec-
tions, four studies in community-acquired pneumonia (CAP), 
and three studies in AECB. A pooled analysis of data was 
performed including a total of 4159 randomized patients.81 
In CAP studies (two previously published),82,83 no significant 
differences were found in pooled clinical response rates 
between cefditoren and comparators (amoxicillin–clavulanic 
acid or cefpodoxime), with percentages of responders ranging 
from 89.2% to 91.8% at the end of therapy, and from 85.9% 
to 90.4% at the end of follow-up.
In AECB, pooled data from the three published   studies84–86 
showed clinical response rates ranging from 85.8% to 91.3% 
at the end of therapy, and from 81.2% to 83.3% at the end of 
follow-up, without significant differences between cefditoren 
and the comparators, ie,   cefuroxime or clarithromycin.
CAP and AECB data were pooled to explore micro-
biologic outcomes.81 With respect to S. pneumoniae, there 
were no significant between-group differences in the rate of 
bacteriologic responders, with rates ranging from 88.5% to 
92.0%. All penicillin nonsusceptible (MIC $0.12 µg/mL) 
isolates of S. pneumoniae in the cefditoren 400 mg group 
(n = 20), 16 of 19 strains (84.2%) in the cefditoren 200 mg 
group, and 16 of 17 strains (94.1% ) in the comparator group 
were eradicated or presumed to be eradicated.81 Among 
penicillin-resistant (MIC $2 µg/mL) isolates, 17 of 18 
(94.4%) isolates in both cefditoren arms were eradicated or 
presumed to be eradicated compared with 10 of 11 (90.9%) 
in the comparator group.81
No significant differences in microbiologic outcome 
with respect to H. influenzae were found between groups, 
with pooled response rates ranging from 82.7% to 86.6%.81
Safety profile
Safety data from all the 13 clinical trials carried out with 
cefditoren in the treatment of community-acquired respira-
tory tract infections were analyzed in a pooled analysis.87 
The safety population was defined as all randomized patients 
with at least one dose intake, and consisted of 4592 patients 
for cefditoren. Cefditoren exhibited an adverse event profile 
similar to that of other antibiotics currently used in the treat-
ment of community-acquired respiratory tract infections, 
with diarrhea being the most frequent adverse event (9.9%) 
followed by nausea (3.5%), abdominal pain (1.8%), and 
dyspepsia (1.1%).87 The rate of vaginosis reported in the 
female population was 3.9%.87
Conclusions
There is increasingly evidence confirming that   bacterial 
eradication should be the primary goal of antibiotic 
  therapy because eradication is the main determinant of 
both   therapeutic outcome and prevention of resistance. 
In the most   prevalent bacterial isolates from community-
acquired respiratory tract infections, that are responsible 
for 80% of consumption of antibiotics in the community, 
there is a global problem of resistance. This means that 
geographic correlations of resistances are consistently 
found between different antibiotics in one species and in 
different species, due to the selection of coresistance and 
coselection of resistance by antibiotic pressure. Resistance 
has traditionally implied the development of new antibiotics 
for which basic efficacy and safety data are required prior 
to licensing. However, during the clinical development 
of a new compound, apart from collecting data on safety 
and tolerance, there is a need to explore the adequacy of 
pharmacodynamic parameters in predicting eradication 
(bacteriologic response) and subsequent clinical efficacy to 
establish breakpoints. Since evolution of bacteria towards 
resistance is a dynamic process, several issues should also 
be addressed after the introduction of a new antibiotic to 
the market. These issues will establish differences between 
the new compound and older antibiotics, and are mainly 
focused on the pharmacodynamic data needed to predict 
selection of resistance and of resistant subpopulations in 
  multibacterial niches (simulating the nasopharynx as the 
specific site for emergence of resistance in respiratory 
tract isolates),   followed in the postmarketing phase by Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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specific   surveillance on resistance to core antibiotics to 
detect   emerging resistances and any link with antibiotic 
consumption in the community.88 This will define the role 
of the new antibiotic, not only from the perspective of 
its therapeutic potential, but also from the ecologic per-
spective, ie,   countering resistances to core antibiotics in 
the   community. The introduction of new antibiotics with 
documented adequate PK/PD and ecologic potentials might 
impact antibiotic policies, ie, decreased use of antibiotics 
with high resistance selection potential.
The documented information on cefditoren gathered from 
published studies in recent years, including those showing its 
ecologic potential in multibacterial niches,11,89 is an example 
of the role for an emerging oral antibacterial facing the cur-
rent antibiotic resistances in community-acquired respiratory 
tract infections.
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